# Polysaccharide Antibody Response Study

> **NCT02429531** · PHASE4 · COMPLETED · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 200 (actual)

## Conditions studied

- Specific Polysaccharide Antibody Deficiency

## Interventions

- **BIOLOGICAL:** Pneumovax 23 (Sanofi Pasteur MSD)
- **BIOLOGICAL:** Typhim Vi (Sanofi Pasteur MSD)

## Key facts

- **NCT ID:** NCT02429531
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429531, "Polysaccharide Antibody Response Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02429531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*